Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cannabis er ikke for børn og unge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Nordic Society of Pediatric Hematology and Oncology (NOPHO)
Vis graf over relationer

BACKGROUND: As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials.

PROCEDURE: A population-based cohort of children treated according to the NOPHO-AML-84, NOPHO-AML-88, and NOPHO-AML-93 trials included 137 eligible survivors among whom 101 (74%) completed a questionnaire and 99 (72%) had otologic and audiologic examination performed including otoscopy (72%), pure tone audiometry (70%), and tympanometry (60%). Eighty-four of 93 (90%) eligible sibling controls completed a similar questionnaire.

RESULTS: At a median of 11 years (range, 4 to 25) after diagnosis, hearing disorders were rare in survivors of childhood AML and in sibling controls, with no significant differences. None had severe or profound hearing loss diagnosed at audiometry. Audiometry detected a subclinical hearing loss ranging from slight to moderate in 19% of the survivors, 5% had low-frequency hearing loss, and 17% had high-frequency hearing loss.

CONCLUSIONS: The frequency of hearing disorders was low, and hearing thresholds in survivors of childhood AML were similar to background populations of comparable age.

OriginalsprogEngelsk
TidsskriftJournal of Pediatric Hematology/Oncology
Vol/bind41
Udgave nummer1
Sider (fra-til)e12-e17
ISSN1077-4114
DOI
StatusUdgivet - jan. 2019

ID: 56614070